nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CACNA1I—NCAM1 interactions—CNTN2—urinary bladder cancer	0.0311	0.0983	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDX1—urinary bladder cancer	0.0242	0.0766	CbGpPWpGaD
Methsuximide—Phenobarbital—CYP4B1—urinary bladder cancer	0.0232	0.881	CrCbGaD
Methsuximide—CACNA1G—NCAM1 interactions—CNTN2—urinary bladder cancer	0.0229	0.0724	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM1 interactions—CNTN2—urinary bladder cancer	0.0222	0.0702	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—CNTN2—urinary bladder cancer	0.0183	0.0578	CbGpPWpGaD
Methsuximide—Irritability—Valrubicin—urinary bladder cancer	0.0171	0.0288	CcSEcCtD
Methsuximide—CYP2C19—urine—urinary bladder cancer	0.0152	0.233	CbGeAlD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—CNTN2—urinary bladder cancer	0.0135	0.0426	CbGpPWpGaD
Methsuximide—Haematuria—Valrubicin—urinary bladder cancer	0.0131	0.0222	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—CNTN2—urinary bladder cancer	0.013	0.0412	CbGpPWpGaD
Methsuximide—Gastrointestinal symptom NOS—Fluorouracil—urinary bladder cancer	0.012	0.0203	CcSEcCtD
Methsuximide—CACNA1H—prostate gland—urinary bladder cancer	0.0114	0.176	CbGeAlD
Methsuximide—Pancytopenia—Mitomycin—urinary bladder cancer	0.0101	0.0171	CcSEcCtD
Methsuximide—CACNA1H—seminal vesicle—urinary bladder cancer	0.00967	0.149	CbGeAlD
Methsuximide—Drowsiness—Mitomycin—urinary bladder cancer	0.00949	0.016	CcSEcCtD
Methsuximide—CYP2C19—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00875	0.0277	CbGpPWpGaD
Methsuximide—Proteinuria—Gemcitabine—urinary bladder cancer	0.00817	0.0138	CcSEcCtD
Methsuximide—CACNA1I—lymph node—urinary bladder cancer	0.00815	0.125	CbGeAlD
Methsuximide—CACNA1H—smooth muscle tissue—urinary bladder cancer	0.0081	0.124	CbGeAlD
Methsuximide—Protein urine present—Gemcitabine—urinary bladder cancer	0.00806	0.0136	CcSEcCtD
Methsuximide—Photophobia—Thiotepa—urinary bladder cancer	0.00801	0.0135	CcSEcCtD
Methsuximide—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00724	0.0122	CcSEcCtD
Methsuximide—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00718	0.0121	CcSEcCtD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0071	0.0224	CbGpPWpGaD
Methsuximide—Vision blurred—Mitomycin—urinary bladder cancer	0.00699	0.0118	CcSEcCtD
Methsuximide—Abdominal pain—Valrubicin—urinary bladder cancer	0.00695	0.0117	CcSEcCtD
Methsuximide—Hiccups—Cisplatin—urinary bladder cancer	0.00669	0.0113	CcSEcCtD
Methsuximide—Leukopenia—Mitomycin—urinary bladder cancer	0.00664	0.0112	CcSEcCtD
Methsuximide—Photophobia—Fluorouracil—urinary bladder cancer	0.00663	0.0112	CcSEcCtD
Methsuximide—CACNA1H—female reproductive system—urinary bladder cancer	0.00624	0.0959	CbGeAlD
Methsuximide—Confusional state—Mitomycin—urinary bladder cancer	0.0061	0.0103	CcSEcCtD
Methsuximide—Diarrhoea—Valrubicin—urinary bladder cancer	0.00601	0.0101	CcSEcCtD
Methsuximide—Ataxia—Thiotepa—urinary bladder cancer	0.00582	0.00983	CcSEcCtD
Methsuximide—Dizziness—Valrubicin—urinary bladder cancer	0.00581	0.00981	CcSEcCtD
Methsuximide—Anorexia—Mitomycin—urinary bladder cancer	0.00577	0.00974	CcSEcCtD
Methsuximide—Vomiting—Valrubicin—urinary bladder cancer	0.00559	0.00943	CcSEcCtD
Methsuximide—Rash—Valrubicin—urinary bladder cancer	0.00554	0.00935	CcSEcCtD
Methsuximide—Dermatitis—Valrubicin—urinary bladder cancer	0.00553	0.00934	CcSEcCtD
Methsuximide—Headache—Valrubicin—urinary bladder cancer	0.0055	0.00929	CcSEcCtD
Methsuximide—Somnolence—Mitomycin—urinary bladder cancer	0.00538	0.00908	CcSEcCtD
Methsuximide—Decreased appetite—Mitomycin—urinary bladder cancer	0.00526	0.00888	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—CNTN2—urinary bladder cancer	0.00524	0.0166	CbGpPWpGaD
Methsuximide—Nausea—Valrubicin—urinary bladder cancer	0.00522	0.00881	CcSEcCtD
Methsuximide—Pancytopenia—Thiotepa—urinary bladder cancer	0.00508	0.00858	CcSEcCtD
Methsuximide—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00499	0.00842	CcSEcCtD
Methsuximide—Irritability—Fluorouracil—urinary bladder cancer	0.00489	0.00825	CcSEcCtD
Methsuximide—Ataxia—Fluorouracil—urinary bladder cancer	0.00482	0.00813	CcSEcCtD
Methsuximide—Irritability—Cisplatin—urinary bladder cancer	0.00463	0.00782	CcSEcCtD
Methsuximide—Haematuria—Thiotepa—urinary bladder cancer	0.00455	0.00768	CcSEcCtD
Methsuximide—Eosinophilia—Fluorouracil—urinary bladder cancer	0.00438	0.0074	CcSEcCtD
Methsuximide—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00428	0.00722	CcSEcCtD
Methsuximide—Pancytopenia—Fluorouracil—urinary bladder cancer	0.0042	0.0071	CcSEcCtD
Methsuximide—Proteinuria—Methotrexate—urinary bladder cancer	0.00418	0.00705	CcSEcCtD
Methsuximide—Diarrhoea—Mitomycin—urinary bladder cancer	0.00414	0.00699	CcSEcCtD
Methsuximide—Protein urine present—Methotrexate—urinary bladder cancer	0.00412	0.00696	CcSEcCtD
Methsuximide—Dizziness—Mitomycin—urinary bladder cancer	0.004	0.00676	CcSEcCtD
Methsuximide—Pancytopenia—Cisplatin—urinary bladder cancer	0.00399	0.00673	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00398	0.00672	CcSEcCtD
Methsuximide—CYP2C19—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00394	0.0124	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—urinary bladder cancer	0.0039	0.0123	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—CNTN2—urinary bladder cancer	0.00386	0.0122	CbGpPWpGaD
Methsuximide—Vomiting—Mitomycin—urinary bladder cancer	0.00385	0.0065	CcSEcCtD
Methsuximide—Haematuria—Gemcitabine—urinary bladder cancer	0.00383	0.00646	CcSEcCtD
Methsuximide—Rash—Mitomycin—urinary bladder cancer	0.00382	0.00644	CcSEcCtD
Methsuximide—Dermatitis—Mitomycin—urinary bladder cancer	0.00381	0.00644	CcSEcCtD
Methsuximide—Headache—Mitomycin—urinary bladder cancer	0.00379	0.0064	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—CNTN2—urinary bladder cancer	0.00374	0.0118	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CNTN2—urinary bladder cancer	0.00374	0.0118	CbGpPWpGaD
Methsuximide—Tension—Thiotepa—urinary bladder cancer	0.00366	0.00618	CcSEcCtD
Methsuximide—CACNA1H—lymph node—urinary bladder cancer	0.00365	0.0561	CbGeAlD
Methsuximide—Pancytopenia—Etoposide—urinary bladder cancer	0.00365	0.00616	CcSEcCtD
Methsuximide—Nervousness—Thiotepa—urinary bladder cancer	0.00362	0.00612	CcSEcCtD
Methsuximide—Nausea—Mitomycin—urinary bladder cancer	0.0036	0.00607	CcSEcCtD
Methsuximide—Vision blurred—Thiotepa—urinary bladder cancer	0.00351	0.00593	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—urinary bladder cancer	0.00344	0.0058	CcSEcCtD
Methsuximide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00341	0.00575	CcSEcCtD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.0034	0.0108	CbGpPWpGaD
Methsuximide—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.0034	0.00574	CcSEcCtD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00336	0.0106	CbGpPWpGaD
Methsuximide—Leukopenia—Thiotepa—urinary bladder cancer	0.00334	0.00564	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—urinary bladder cancer	0.00318	0.00537	CcSEcCtD
Methsuximide—Antipyrine—PTGS2—urinary bladder cancer	0.00312	0.118	CrCbGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—SRC—urinary bladder cancer	0.00312	0.00986	CbGpPWpGaD
Methsuximide—Confusional state—Thiotepa—urinary bladder cancer	0.00307	0.00518	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—urinary bladder cancer	0.00302	0.00956	CbGpPWpGaD
Methsuximide—Erythema multiforme—Etoposide—urinary bladder cancer	0.00291	0.00491	CcSEcCtD
Methsuximide—Vision blurred—Fluorouracil—urinary bladder cancer	0.00291	0.00491	CcSEcCtD
Methsuximide—Anorexia—Thiotepa—urinary bladder cancer	0.0029	0.0049	CcSEcCtD
Methsuximide—Leukopenia—Gemcitabine—urinary bladder cancer	0.00281	0.00474	CcSEcCtD
Methsuximide—Leukopenia—Fluorouracil—urinary bladder cancer	0.00276	0.00466	CcSEcCtD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00276	0.00872	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CNTN2—urinary bladder cancer	0.00276	0.00872	CbGpPWpGaD
Methsuximide—Vision blurred—Cisplatin—urinary bladder cancer	0.00276	0.00465	CcSEcCtD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00275	0.00869	CbGpPWpGaD
Methsuximide—Somnolence—Thiotepa—urinary bladder cancer	0.00271	0.00457	CcSEcCtD
Methsuximide—CYP2C19—vagina—urinary bladder cancer	0.00269	0.0413	CbGeAlD
Methsuximide—CACNA1H—Developmental Biology—CNTN2—urinary bladder cancer	0.00267	0.00844	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—urinary bladder cancer	0.00267	0.00844	CbGpPWpGaD
Methsuximide—Decreased appetite—Thiotepa—urinary bladder cancer	0.00265	0.00447	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00263	0.00444	CcSEcCtD
Methsuximide—Leukopenia—Cisplatin—urinary bladder cancer	0.00262	0.00442	CcSEcCtD
Methsuximide—Constipation—Thiotepa—urinary bladder cancer	0.0026	0.00439	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—KRAS—urinary bladder cancer	0.00258	0.00816	CbGpPWpGaD
Methsuximide—Irritability—Methotrexate—urinary bladder cancer	0.00254	0.00429	CcSEcCtD
Methsuximide—Confusional state—Fluorouracil—urinary bladder cancer	0.00254	0.00429	CcSEcCtD
Methsuximide—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00251	0.00423	CcSEcCtD
Methsuximide—Ataxia—Methotrexate—urinary bladder cancer	0.00251	0.00423	CcSEcCtD
Methsuximide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00249	0.0042	CcSEcCtD
Methsuximide—Anorexia—Gemcitabine—urinary bladder cancer	0.00244	0.00412	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—urinary bladder cancer	0.00242	0.00765	CbGpPWpGaD
Methsuximide—Urticaria—Thiotepa—urinary bladder cancer	0.00242	0.00408	CcSEcCtD
Methsuximide—Abdominal pain—Thiotepa—urinary bladder cancer	0.00241	0.00406	CcSEcCtD
Methsuximide—Anorexia—Fluorouracil—urinary bladder cancer	0.0024	0.00405	CcSEcCtD
Methsuximide—Leukopenia—Etoposide—urinary bladder cancer	0.0024	0.00405	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—RHOA—urinary bladder cancer	0.00239	0.00755	CbGpPWpGaD
Methsuximide—Ataxia—Epirubicin—urinary bladder cancer	0.00234	0.00396	CcSEcCtD
Methsuximide—Insomnia—Gemcitabine—urinary bladder cancer	0.00232	0.00391	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—SRC—urinary bladder cancer	0.0023	0.00727	CbGpPWpGaD
Methsuximide—Eosinophilia—Methotrexate—urinary bladder cancer	0.00228	0.00385	CcSEcCtD
Methsuximide—Insomnia—Fluorouracil—urinary bladder cancer	0.00228	0.00384	CcSEcCtD
Methsuximide—Somnolence—Gemcitabine—urinary bladder cancer	0.00228	0.00384	CcSEcCtD
Methsuximide—Anorexia—Cisplatin—urinary bladder cancer	0.00227	0.00384	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—urinary bladder cancer	0.00225	0.00713	CbGpPWpGaD
Methsuximide—Somnolence—Fluorouracil—urinary bladder cancer	0.00224	0.00378	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—SRC—urinary bladder cancer	0.00223	0.00704	CbGpPWpGaD
Methsuximide—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00223	0.00376	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00221	0.00373	CcSEcCtD
Methsuximide—Confusional state—Etoposide—urinary bladder cancer	0.0022	0.00372	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—HRAS—urinary bladder cancer	0.00219	0.00694	CbGpPWpGaD
Methsuximide—Constipation—Gemcitabine—urinary bladder cancer	0.00219	0.0037	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—urinary bladder cancer	0.00219	0.00692	CbGpPWpGaD
Methsuximide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00219	0.00369	CcSEcCtD
Methsuximide—Pancytopenia—Methotrexate—urinary bladder cancer	0.00219	0.00369	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00217	0.00367	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—urinary bladder cancer	0.00217	0.00366	CcSEcCtD
Methsuximide—Eosinophilia—Epirubicin—urinary bladder cancer	0.00213	0.0036	CcSEcCtD
Methsuximide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00211	0.00356	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CXCL8—urinary bladder cancer	0.0021	0.00663	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00209	0.00662	CbGpPWpGaD
Methsuximide—Anorexia—Etoposide—urinary bladder cancer	0.00208	0.00352	CcSEcCtD
Methsuximide—Diarrhoea—Thiotepa—urinary bladder cancer	0.00208	0.00352	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—urinary bladder cancer	0.00208	0.00656	CbGpPWpGaD
Methsuximide—Decreased appetite—Cisplatin—urinary bladder cancer	0.00207	0.0035	CcSEcCtD
Methsuximide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00207	0.0035	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00206	0.00348	CcSEcCtD
Methsuximide—Drowsiness—Methotrexate—urinary bladder cancer	0.00205	0.00347	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—urinary bladder cancer	0.00205	0.00346	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00204	0.00344	CcSEcCtD
Methsuximide—Dizziness—Thiotepa—urinary bladder cancer	0.00201	0.0034	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—IL2—urinary bladder cancer	0.002	0.00633	CbGpPWpGaD
Methsuximide—Urticaria—Fluorouracil—urinary bladder cancer	0.002	0.00338	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00197	0.00333	CcSEcCtD
Methsuximide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00197	0.00332	CcSEcCtD
Methsuximide—Haematuria—Methotrexate—urinary bladder cancer	0.00196	0.00331	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—urinary bladder cancer	0.00195	0.00329	CcSEcCtD
Methsuximide—Somnolence—Etoposide—urinary bladder cancer	0.00194	0.00328	CcSEcCtD
Methsuximide—Vomiting—Thiotepa—urinary bladder cancer	0.00194	0.00327	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—urinary bladder cancer	0.00192	0.00324	CcSEcCtD
Methsuximide—Rash—Thiotepa—urinary bladder cancer	0.00192	0.00324	CcSEcCtD
Methsuximide—Dermatitis—Thiotepa—urinary bladder cancer	0.00192	0.00324	CcSEcCtD
Methsuximide—Headache—Thiotepa—urinary bladder cancer	0.00191	0.00322	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00191	0.00322	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—urinary bladder cancer	0.0019	0.00602	CbGpPWpGaD
Methsuximide—Decreased appetite—Etoposide—urinary bladder cancer	0.0019	0.00321	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00189	0.0032	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00189	0.00319	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTZ1—urinary bladder cancer	0.00188	0.00593	CbGpPWpGaD
Methsuximide—Constipation—Etoposide—urinary bladder cancer	0.00187	0.00316	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00185	0.00585	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—KRAS—urinary bladder cancer	0.00184	0.00583	CbGpPWpGaD
Methsuximide—Haematuria—Epirubicin—urinary bladder cancer	0.00183	0.00309	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	0.00181	0.00572	CbGpPWpGaD
Methsuximide—Nausea—Thiotepa—urinary bladder cancer	0.00181	0.00305	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—urinary bladder cancer	0.0018	0.00305	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—urinary bladder cancer	0.0018	0.00304	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00179	0.00302	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTO2—urinary bladder cancer	0.00178	0.00562	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—NAT1—urinary bladder cancer	0.00178	0.00562	CbGpPWpGaD
Methsuximide—Drowsiness—Doxorubicin—urinary bladder cancer	0.00178	0.003	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00176	0.00298	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00175	0.00555	CbGpPWpGaD
Methsuximide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00175	0.00296	CcSEcCtD
Methsuximide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00174	0.00294	CcSEcCtD
Methsuximide—Urticaria—Etoposide—urinary bladder cancer	0.00174	0.00293	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—urinary bladder cancer	0.00173	0.00292	CcSEcCtD
Methsuximide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00172	0.00291	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—urinary bladder cancer	0.0017	0.00286	CcSEcCtD
Methsuximide—Dizziness—Fluorouracil—urinary bladder cancer	0.00166	0.00281	CcSEcCtD
Methsuximide—Diarrhoea—Cisplatin—urinary bladder cancer	0.00163	0.00276	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00163	0.00275	CcSEcCtD
Methsuximide—Vomiting—Gemcitabine—urinary bladder cancer	0.00163	0.00275	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—UGT2B7—urinary bladder cancer	0.00163	0.00514	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—urinary bladder cancer	0.00162	0.00512	CbGpPWpGaD
Methsuximide—Rash—Gemcitabine—urinary bladder cancer	0.00161	0.00273	CcSEcCtD
Methsuximide—Dermatitis—Gemcitabine—urinary bladder cancer	0.00161	0.00272	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.0016	0.00507	CbGpPWpGaD
Methsuximide—Headache—Gemcitabine—urinary bladder cancer	0.0016	0.00271	CcSEcCtD
Methsuximide—Vomiting—Fluorouracil—urinary bladder cancer	0.0016	0.0027	CcSEcCtD
Methsuximide—Rash—Fluorouracil—urinary bladder cancer	0.00159	0.00268	CcSEcCtD
Methsuximide—Dermatitis—Fluorouracil—urinary bladder cancer	0.00159	0.00268	CcSEcCtD
Methsuximide—Headache—Fluorouracil—urinary bladder cancer	0.00158	0.00266	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—urinary bladder cancer	0.00157	0.00495	CbGpPWpGaD
Methsuximide—Nausea—Gemcitabine—urinary bladder cancer	0.00152	0.00257	CcSEcCtD
Methsuximide—Vomiting—Cisplatin—urinary bladder cancer	0.00152	0.00256	CcSEcCtD
Methsuximide—Vision blurred—Methotrexate—urinary bladder cancer	0.00151	0.00255	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00151	0.00255	CcSEcCtD
Methsuximide—Rash—Cisplatin—urinary bladder cancer	0.0015	0.00254	CcSEcCtD
Methsuximide—Dermatitis—Cisplatin—urinary bladder cancer	0.0015	0.00254	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—urinary bladder cancer	0.0015	0.00253	CcSEcCtD
Methsuximide—Nausea—Fluorouracil—urinary bladder cancer	0.0015	0.00252	CcSEcCtD
Methsuximide—Tension—Epirubicin—urinary bladder cancer	0.00147	0.00249	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	0.00146	0.00463	CbGpPWpGaD
Methsuximide—Nervousness—Epirubicin—urinary bladder cancer	0.00146	0.00246	CcSEcCtD
Methsuximide—Dizziness—Etoposide—urinary bladder cancer	0.00145	0.00244	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00144	0.00457	CbGpPWpGaD
Methsuximide—Leukopenia—Methotrexate—urinary bladder cancer	0.00144	0.00243	CcSEcCtD
Methsuximide—Nausea—Cisplatin—urinary bladder cancer	0.00142	0.00239	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—urinary bladder cancer	0.00142	0.00239	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—NCOR1—urinary bladder cancer	0.0014	0.00442	CbGpPWpGaD
Methsuximide—Vomiting—Etoposide—urinary bladder cancer	0.00139	0.00235	CcSEcCtD
Methsuximide—Rash—Etoposide—urinary bladder cancer	0.00138	0.00233	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—urinary bladder cancer	0.00138	0.00233	CcSEcCtD
Methsuximide—Headache—Etoposide—urinary bladder cancer	0.00137	0.00231	CcSEcCtD
Methsuximide—Tension—Doxorubicin—urinary bladder cancer	0.00136	0.0023	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—urinary bladder cancer	0.00135	0.00228	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—urinary bladder cancer	0.00134	0.00227	CcSEcCtD
Methsuximide—Confusional state—Methotrexate—urinary bladder cancer	0.00132	0.00223	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—urinary bladder cancer	0.00131	0.00221	CcSEcCtD
Methsuximide—Nausea—Etoposide—urinary bladder cancer	0.0013	0.00219	CcSEcCtD
Methsuximide—Anorexia—Methotrexate—urinary bladder cancer	0.00125	0.00211	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—urinary bladder cancer	0.00124	0.0021	CcSEcCtD
Methsuximide—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00124	0.00392	CbGpPWpGaD
Methsuximide—Confusional state—Epirubicin—urinary bladder cancer	0.00124	0.00209	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—RHOA—urinary bladder cancer	0.00122	0.00386	CbGpPWpGaD
Methsuximide—Insomnia—Methotrexate—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Methsuximide—Anorexia—Epirubicin—urinary bladder cancer	0.00117	0.00197	CcSEcCtD
Methsuximide—Somnolence—Methotrexate—urinary bladder cancer	0.00116	0.00197	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Methsuximide—Decreased appetite—Methotrexate—urinary bladder cancer	0.00114	0.00192	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00113	0.00191	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—ERBB2—urinary bladder cancer	0.00113	0.00358	CbGpPWpGaD
Methsuximide—Insomnia—Epirubicin—urinary bladder cancer	0.00111	0.00187	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—CDK4—urinary bladder cancer	0.0011	0.00349	CbGpPWpGaD
Methsuximide—Somnolence—Epirubicin—urinary bladder cancer	0.00109	0.00184	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—urinary bladder cancer	0.00108	0.00183	CcSEcCtD
Methsuximide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00108	0.00182	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00107	0.00181	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—urinary bladder cancer	0.00107	0.0018	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00106	0.00179	CcSEcCtD
Methsuximide—Constipation—Epirubicin—urinary bladder cancer	0.00105	0.00177	CcSEcCtD
Methsuximide—Urticaria—Methotrexate—urinary bladder cancer	0.00104	0.00176	CcSEcCtD
Methsuximide—Abdominal pain—Methotrexate—urinary bladder cancer	0.00104	0.00175	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—NCOR1—urinary bladder cancer	0.00103	0.00326	CbGpPWpGaD
Methsuximide—Insomnia—Doxorubicin—urinary bladder cancer	0.00103	0.00173	CcSEcCtD
Methsuximide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00101	0.00171	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—urinary bladder cancer	0.00101	0.0017	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—PPARG—urinary bladder cancer	0.001	0.00317	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.001	0.00169	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—NCOR1—urinary bladder cancer	0.000999	0.00316	CbGpPWpGaD
Methsuximide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000986	0.00166	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000979	0.00165	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.000975	0.00308	CbGpPWpGaD
Methsuximide—Urticaria—Epirubicin—urinary bladder cancer	0.000974	0.00164	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—urinary bladder cancer	0.00097	0.00164	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—MMP9—urinary bladder cancer	0.00097	0.00307	CbGpPWpGaD
Methsuximide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000969	0.00164	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—CREBBP—urinary bladder cancer	0.000963	0.00305	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000961	0.00304	CbGpPWpGaD
Methsuximide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000934	0.00158	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000927	0.00157	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—urinary bladder cancer	0.000901	0.00152	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—RHOA—urinary bladder cancer	0.0009	0.00285	CbGpPWpGaD
Methsuximide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000896	0.00151	CcSEcCtD
Methsuximide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000896	0.00151	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—SRC—urinary bladder cancer	0.000894	0.00283	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—RHOA—urinary bladder cancer	0.000872	0.00276	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—RHOA—urinary bladder cancer	0.000872	0.00276	CbGpPWpGaD
Methsuximide—Dizziness—Methotrexate—urinary bladder cancer	0.000866	0.00146	CcSEcCtD
Methsuximide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000839	0.00142	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—ERBB2—urinary bladder cancer	0.000833	0.00264	CbGpPWpGaD
Methsuximide—Vomiting—Methotrexate—urinary bladder cancer	0.000833	0.00141	CcSEcCtD
Methsuximide—Rash—Methotrexate—urinary bladder cancer	0.000826	0.00139	CcSEcCtD
Methsuximide—Dermatitis—Methotrexate—urinary bladder cancer	0.000825	0.00139	CcSEcCtD
Methsuximide—Headache—Methotrexate—urinary bladder cancer	0.00082	0.00139	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—CDK4—urinary bladder cancer	0.000814	0.00257	CbGpPWpGaD
Methsuximide—Dizziness—Epirubicin—urinary bladder cancer	0.00081	0.00137	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—ERBB2—urinary bladder cancer	0.000807	0.00255	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—urinary bladder cancer	0.000807	0.00255	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CDK4—urinary bladder cancer	0.000788	0.00249	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EGFR—urinary bladder cancer	0.000784	0.00248	CbGpPWpGaD
Methsuximide—Vomiting—Epirubicin—urinary bladder cancer	0.000779	0.00132	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000779	0.00246	CbGpPWpGaD
Methsuximide—Nausea—Methotrexate—urinary bladder cancer	0.000778	0.00131	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000776	0.00131	CcSEcCtD
Methsuximide—Rash—Epirubicin—urinary bladder cancer	0.000773	0.0013	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—urinary bladder cancer	0.000772	0.0013	CcSEcCtD
Methsuximide—Headache—Epirubicin—urinary bladder cancer	0.000768	0.0013	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000756	0.00239	CbGpPWpGaD
Methsuximide—Dizziness—Doxorubicin—urinary bladder cancer	0.00075	0.00127	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—KRAS—urinary bladder cancer	0.00074	0.00234	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PPARG—urinary bladder cancer	0.000739	0.00234	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000729	0.00231	CbGpPWpGaD
Methsuximide—Nausea—Epirubicin—urinary bladder cancer	0.000728	0.00123	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—urinary bladder cancer	0.000721	0.00122	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—PPARG—urinary bladder cancer	0.000716	0.00226	CbGpPWpGaD
Methsuximide—Rash—Doxorubicin—urinary bladder cancer	0.000715	0.00121	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—MMP9—urinary bladder cancer	0.000715	0.00226	CbGpPWpGaD
Methsuximide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000714	0.00121	CcSEcCtD
Methsuximide—Headache—Doxorubicin—urinary bladder cancer	0.00071	0.0012	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—CREBBP—urinary bladder cancer	0.00071	0.00225	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—urinary bladder cancer	0.000692	0.00219	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—urinary bladder cancer	0.000692	0.00219	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CREBBP—urinary bladder cancer	0.000688	0.00218	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—urinary bladder cancer	0.000674	0.00114	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—SRC—urinary bladder cancer	0.000659	0.00208	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EP300—urinary bladder cancer	0.000656	0.00207	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—RHOA—urinary bladder cancer	0.000642	0.00203	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—SRC—urinary bladder cancer	0.000638	0.00202	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SRC—urinary bladder cancer	0.000638	0.00202	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—urinary bladder cancer	0.000629	0.00199	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—RHOA—urinary bladder cancer	0.000622	0.00197	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—urinary bladder cancer	0.000595	0.00188	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EGFR—urinary bladder cancer	0.000578	0.00183	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—urinary bladder cancer	0.000576	0.00182	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000562	0.00178	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—urinary bladder cancer	0.00056	0.00177	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—urinary bladder cancer	0.000559	0.00177	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—urinary bladder cancer	0.000546	0.00173	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TNF—urinary bladder cancer	0.000533	0.00168	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—urinary bladder cancer	0.000529	0.00167	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—urinary bladder cancer	0.000528	0.00167	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000524	0.00166	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000517	0.00163	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—urinary bladder cancer	0.00051	0.00161	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—urinary bladder cancer	0.000494	0.00156	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EP300—urinary bladder cancer	0.000484	0.00153	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000481	0.00152	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000475	0.0015	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SRC—urinary bladder cancer	0.00047	0.00149	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EP300—urinary bladder cancer	0.000468	0.00148	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—urinary bladder cancer	0.000464	0.00147	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SRC—urinary bladder cancer	0.000456	0.00144	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—urinary bladder cancer	0.000449	0.00142	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—urinary bladder cancer	0.000449	0.00142	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—urinary bladder cancer	0.000412	0.0013	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—urinary bladder cancer	0.000399	0.00126	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TNF—urinary bladder cancer	0.000393	0.00124	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—urinary bladder cancer	0.000389	0.00123	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TNF—urinary bladder cancer	0.00038	0.0012	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—urinary bladder cancer	0.000377	0.00119	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—urinary bladder cancer	0.000331	0.00105	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000321	0.00101	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—urinary bladder cancer	0.000321	0.00101	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000304	0.000962	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000304	0.000962	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000299	0.000946	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000278	0.00088	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	0.00025	0.000792	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	0.000237	0.000748	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	0.000231	0.000729	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000185	0.000585	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	0.000184	0.000583	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000177	0.00056	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	0.000167	0.000527	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	0.000144	0.000455	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	0.000133	0.000421	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	0.000133	0.000421	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000132	0.000419	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	0.000129	0.000409	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000127	0.000402	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	0.000107	0.00034	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000104	0.00033	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.09e-05	0.000287	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	8.96e-05	0.000283	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.67e-05	0.000274	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	8.33e-05	0.000263	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	8.23e-05	0.00026	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	8.23e-05	0.00026	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	7.88e-05	0.000249	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	7.74e-05	0.000245	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	7.27e-05	0.00023	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	5.9e-05	0.000187	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	5.67e-05	0.000179	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	4.64e-05	0.000147	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.05e-05	0.000128	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.86e-05	0.000122	CbGpPWpGaD
